Join Us at Biopharma Leadership & Innovation Conclave
#BLIConclave
8th October, 2025
10:00 AM - 8:00 PM
(Followed by Cocktails and Dinner)
Hilton Garden Inn Pune Hinjawadi
About the Event
Global health needs are changing fast. New challenges like complex diseases, rare conditions, and personalised treatments are transforming healthcare. At the same time, technology is changing how new therapies are discovered, developed, and delivered.
This shift opens a huge opportunity for biopharma in India. India has the talent, manufacturing strength and cost advantage to lead the next wave of biopharma innovation. However, to capture this potential, India must move faster, invest smarter, build strong partnerships, and build robust regulatory systems. To drive this transformation, Express Pharma is hosting the Biopharma Leadership Conclave, a platform to discuss how India can rise as a global leader in innovative, affordable biopharma, under the theme, 'The future of biopharma: Made in India'.To be held in Pune on October 8, 2025, it will bring together industry leaders, policymakers, researchers and investors to chart the roadmap for India’s growth in biopharma. The conclave will explore strategies to drive innovative, competitive and accessible biopharma solutions from India for the world. Read more
Why India can lead the global biopharma revolution
From biosimilars to breakthroughs – India’s innovation pathway
Biopharma funding playbook
Manufacturing 4.0 in biopharma
Regulatory roadmap 2035: Fast tracking India’s biopharma future
Strengthening supply chains for biologics and biosimilars
Cell and gene therapy: India’s next big bet
Regulation meets quality: Accelerating safe, affordable biopharma
Accelerating talent-building for the biopharma industry
Formulating for next-gen biotherapeutics
Digitalisation and automation in biopharma: Keys to progress
Biopharma companies manufacturing biosimilars, biologics, and cell and gene therapies.
Senior leaders from:
Manufacturing
Operations
Production
Research & Development (R&D)
Process development - Upstream and downstream
Quality (QA /QC)
Engineering & Technical
Fill & finish
Purchase/Procurement & Supply chain
Packaging
Regulatory Affairs
Government representatives from DBT, CSIR, BIRAC and other relevant agencies
Mr Prasun Kumar Guha
Head & VP – Regulatory Affairs, Biologics, Dr Reddy’s Laboratories
Prof Samir Kulkarni
Head Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Mumbai
Mr Shrikrishna Chunekar
Director - QA, Serum Institute of India
Dr Anil Yadav
Technical Director, Raut Serums India
Mr Mukesh Patale
Group Lead-USP MSAT, Biologics Division, Dr Reddy’s Laboratories
Dr Sudeep Kumar
COO, TechInvention Lifecare
Dr Yashwant Chavan
MD, geneOmbio Technologies
Dr Venkata Ramana
Chief Scientific Officer, Reliance Life Sciences
Dr Mukesh Kumar
Chief Scientific Officer, CLINEXEL
Mr Usman Ali Ansari
Sr. Manager - Biotech Production, Bharat Serums and Vaccines (Mankind)
Mr Pankaj Gour
Sr General Manager, Enzene Biosciences
Ms Sonia Gandhi
DGM & Head (Regulatory Affairs & Policy Advocacy), BIRAC
Ms Sheetal Raut
Sr Manager & Bioassay Team Lead - Advanced Biotech Lab, Ipca Laboratories
Mr Vishal Pavitrakar
Senior Director Global Regulatory Affairs-CMC, Alvotech
Mr Jayachandran Ramalingam
GM, Head - Biosimilars QC, Serum Institute of India
Mr Shital Jain
DGM, Serum Institute of India
Mr Garet Jacob Fernandes
Product Manager, CSE India
Dr Shuvankar Ballav
Manager and Lead - Regulatory Affairs (ABL), Ipca Laboratories